Mymetics Corp (MYMX)

[Work Harder]

From that, Antonio Lanzavecchia

is an Italian immunologist

and since 2009 is professor of Human Immunology at the Swiss Federal Institute of Technology Zurich. Since January 2014 he had been appointed President of the Fondazione Regionale per la Ricerca Biomedica of the Region Lombardy, Italy.

https://en.wikipedia.org/wiki/Antonio_Lanzavecchia

https://search.usi.ch/en/people/80896433dd0440f696fdfd2edc1b47b2/lanzavecchia-antonio

Antibody-mediated immune exclusion of HIV

https://europepmc.org/article/PMC/5604883

US institutes and research centers receive thousands of francs from multinationals and banks. At risk is the independence of research and the educational freedom of students, unaware of everything ...

The investigation consulted the University of Italian Switzerland (Usi) on the matter.

Its members include the Biomedicine Research Institute (Irb), created in Bellinzona in 2000 and affiliated with the USI. The IRB deals with immunology, experimenting on human and animal cells: it is here that the first "human mouse" was created last April to try to fight Sida and Sars. Usi and Irb have close ties: the director of the scientific committee is the dean of the Ticino university, the immunologist Marco Baggiolini. The research is instead directed by the Italian Antonio Lanzavecchia.

But as industries and public institutions invest millions in biotechnology, citizens are sharing such research less and less. The issue is ethically controversial. Especially since the Swiss, in 1998, authorized the production and sale of genetically modified animals and plants.

The second important private funding comes from the third world biotech group, after the Americans Amgen and Genentech, the Geneva-based Serono, which already sponsors universities around the world. From this, the IRB has so far received 1.9 million francs, but has allocated 4.8 million until 2006 to promote the Ticino Biopolo. Its manager, Ernesto Bertarelli, sits on the board of directors of Ubs.

"Funding of this type is frequent in research institutes" replies to the Lanzavecchia Inquiry. "They are of mutual benefit and do not affect the freedom of research in the slightest," he adds

The aim is to support biotech in the canton, including by buying or selling patents.

https://translate.google.com/translate?hl=en&sl=it&u=http://www.marcojeitziner.ch/0704usi.htm&prev=search&pto=aue